

**COHN LIFLAND PEARLMAN
HERRMANN & KNOFF LLP**

Peter S. Pearlman
Park 80 West – Plaza One
250 Pehle Avenue, Suite 401
Saddle Brook, New Jersey 07663
(201) 845-9600 (telephone)
(201) 845-9423 (fax)
psp@njlawfirm.com

Attorney for the Direct Purchaser Plaintiff Class

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

IN RE: LIPITOR ANTITRUST
LITIGATION

MDL No. 2332

This document relates to:

Master Docket No. 3:12-cv-2389
(PGS/JBD)

Direct Purchaser Class Actions

**DECLARATION OF PETER S. PEARLMAN IN SUPPORT OF
DIRECT PURCHASER CLASS PLAINTIFFS' MOTION FOR
FINAL APPROVAL OF PROPOSED SETTLEMENT**

I, Peter S. Pearlman, am an attorney duly authorized to practice law in the State of New Jersey and am admitted to practice before the United States District Court for the District of New Jersey. I am Liaison counsel for the Direct Plaintiff Class Plaintiffs ("Plaintiffs") in the above captioned litigation. I submit this declaration in support of Plaintiffs' Motion for Final Approval of Class Action Settlement.

1. On March 22, 2024, Class Counsel, through the Court-appointed claims administrator, caused notice to be given to Class members via first-class mail. The notice detailed, inter alia: (a) the terms of the Settlement; (b) the procedures and deadline for objecting to either the Settlement and/or Class Counsel's Fee Submission; (c) the procedures and deadlines for submitting claim forms and/or receiving Settlement funds; and (d) the location, date, and time of the Court's final fairness hearing. *See* Pearlman Decl. at Ex. 1 hereto (Declaration of Tina Chiango, RG/2 Claims Administration LLC, Regarding Notice of the Proposed Settlement to the Direct Purchaser Class).

2. On April 24, 2024, Class Counsel filed their Fee Submission, which addressed attorneys' fees, reimbursement of costs and service awards to the named plaintiffs. *See* ECF No. 1397. The Fee Submission was posted on the websites of Lead Class Counsel.

3. No objections to the Settlement were received by Lead Class Counsel or the claims administrator.

4. No objections to the Fee Submission or Revised Fee Submission were received by Lead Class Counsel.

5. Attached as Exhibit 1 hereto is a true and correct copy of the Declaration of Tina Chiango, RG/2 Claims Administration LLC, Regarding Notice of the Proposed Settlement to the Direct Purchaser Class.

I declare under penalty of perjury that the forgoing is true and correct.

Executed this 29th day of May, 2024.

/s/Peter S. Pearlman

Peter S. Pearlman

EXHIBIT

1

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

IN RE: LIPITOR ANTITRUST
LITIGATION

This document relates to:

Direct Purchaser Class Actions

MDL No. 2332

Master Docket No. 3:12-cv-2389
(PGS/JBD)

**DECLARATION OF TINA CHIANGO OF RG/2 CLAIMS
ADMINISTRATION LLC REGARDING NOTICE OF THE PROPOSED
SETTLEMENT TO THE DIRECT PURCHASER CLASS**

I, Tina Chiango, hereby declare as follows:

1. I am the Director of Claims Administration for RG/2 Claims Administration LLC (“RG/2”), whose address is 30 South 17th Street, Philadelphia, PA 19103. In that role, I oversee the intake and management of the claim administrations of the ongoing class action settlements handled by RG/2 Claims, including the creation and implementation of legal notice plans. I have been involved in the development and implementation of plans for class action notification for more than 25 years.

2. RG/2 Claims was established in 2002 as a full service class action notice and claims administrator, providing notice and administration services for a broad range of collective actions, including but not limited to antitrust, securities, consumer, and employment cases. RG/2 Claims specializes in the creation,

development and implementation of legal notification plans. Accordingly, RG/2 Claims is familiar with, and guided by Constitutional due process provisions, rules of states and local jurisdictions, and the relevant case law relating to legal notification. Since 2002, RG/2 Claims has administered and distributed in excess of \$2.0 billion in class-action settlement proceeds.

3. In accordance with the Court's Preliminary Approval Order dated March 8, 2024 (ECF No. 1374), RG/2 mailed the Settlement Notice to Class members via first-class mail on March 22, 2024.

4. A copy of the Settlement Notice that was mail to Class members is attached hereto as Exhibit A.

5. The Settlement Notice was successfully mailed to all Class members. Settlement Notices to all but two Class members were successfully delivered on the first attempt. For the other two Class members, RG/2 received undeliverable Notices on the first attempt, but new addresses for those Class members were promptly identified and copies of the Notice were successfully delivered to those new addresses, neither of which was returned as undeliverable.

6. The Settlement Notice advised Class members that they could object to the proposed Settlement or opt out of the Class, provided they do so by the deadline of May 8, 2024.¹

¹ Contemporaneously with the Settlement Notice, Class members were mailed

7. RG/2 received no objections to the proposed Settlement and no Class members opted out of the Class.

I declare under penalty of perjury that the forgoing is true and correct.

Executed this 29th day of May, 2024.


TINA CHIANGO

individualized, pre-populated claim forms. The Settlement Notice (and claim forms) instructed Class members to complete, sign and return or postmark claim forms by the deadline of May 22, 2024. RG/2 is currently processing claim forms that have been received, and motion for the Court's review and approval concerning the distribution of funds to Class members will be forthcoming.

EXHIBIT A

UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY

In re: Lipitor Antitrust Litigation

MDL No. 2332, No. 12-cv-2389

Si desea recibir esta notificación en español, llámenos al 866-742-4955

PROOF OF CLAIM AND RELEASE

Your claim must be postmarked by: May 22, 2024

Notice ID:

INTRODUCTION

On March 8, 2024, the Court in the above-entitled action (the “Action”) preliminarily approved a \$93,000,000 settlement in a class action lawsuit brought by Drogueria Betances, LLC, Professional Drug Company, Inc., Rochester Drug Co-Operative, Inc., Stephen L. LaFrance Holdings, Inc., and Value Drug Company (collectively “Plaintiffs” or “Class Representatives”) against Pfizer Inc., Pfizer Manufacturing Ireland, Warner-Lambert Co., and Warner-Lambert Co. LLC (collectively, “Pfizer”) and Ranbaxy Inc., Ranbaxy Laboratories Limited, and Ranbaxy Pharmaceuticals, Inc. (collectively, “Ranbaxy”). The Settlement is with Pfizer only.

The notice of class action Settlement dated March 23, 2024, which was mailed to Class members with this claim form, and which is available at <https://www.hbsslaw.com/cases/lipitor-antitrust>, <https://garwingerstein.com/settlements/in-re-lipitor-antitrust-litigation/>, and <https://bergermontague.com/cases/in-re-lipitor-antitrust-lawsuit/>, summarizes both the litigation and terms of the Settlement. As set forth in the notice, the Settlement is with Pfizer only and does not resolve any of the claims against Ranbaxy. The purpose of this Proof of Claim Form and Release is to ensure that you are able to participate in the distribution of the Settlement funds from the Settlement with Pfizer, net of attorneys’ fees, service awards to Class Representatives, and other costs awarded by the Court (the “Net Settlement Fund”).

In order for the Claims Administrator to make the proper calculation of your *pro rata* share of the Net Settlement Fund, please either (a) verify the accuracy of the net purchase volumes listed in Part II.A of this Proof of Claim and Release Form that are derived from purchase data produced in this Action or (b) submit the data required in Part II.B of this Proof of Claim and Release Form.

PART I: CLAIMANT IDENTIFICATION

Please provide this information. In addition, if purchases were made in a name other than the Claimant’s name (for example, if you are filing this Proof of Claim and Release Form based on an assignment), please include documentation of your right to assert a claim with respect to those claimed purchases.

Employer Tax Identification Number: _____

Claimant Name & Address:

Please make any changes or corrections below:

Person overseeing the claims process for Claimant (who can be contacted if there are questions regarding this claim):

First Name: _____ MI: _____ Last Name: _____

Phone Number: (_____) _____ - _____ Email Address: _____

PART II: CLASS MEMBER’S QUALIFYING PURCHASES OF BRAND AND/OR GENERIC LIPITOR TABLETS

A. The Claims Administrator, in conjunction with the direct purchaser plaintiffs’ economic expert, has calculated each Class member’s qualifying direct purchases of brand Lipitor tablets directly from Pfizer during the period of June 28, 2011 through May 29, 2014, and direct purchases of generic Lipitor directly from Ranbaxy Inc., Ranbaxy Laboratories Limited, and Ranbaxy Pharmaceuticals, Inc. (collectively, “Ranbaxy”) or Watson Pharmaceuticals, Inc. (“Watson”) during the period of November 30, 2011 through May 28, 2012. The initial calculations are based upon brand and generic Lipitor sales data produced by Pfizer, Ranbaxy, and Watson in the Action. If and when the Claims Administrator learns of additional data or claims, the calculations may change. In addition, your calculation may change as a result of other information submitted during the claims administration process. **To repeat, the initial calculations are subject to change.**

Each Class member should verify the accuracy of the total net purchase volumes listed below. **If you agree that the total net purchase volumes computed for your company are accurate, you should sign on page 6 of this Proof of Claim and Release Form and mail it to the Claims Administrator postmarked no later than May 22, 2024.** If you verify the accuracy of the total net purchase volumes listed below, you will not be required to produce any purchase data as part of the claims administration process, but you are waiving the right to challenge or appeal the Claims Administrator’s determination regarding your pro rata distribution amount on the basis that the distribution amount would have been different had it been calculated using your own purchase records. **If you believe the total net purchase volumes listed for your company below are not accurate, you may submit purchase records, in electronic format as described in Part II.B below; any such data must be mailed to the Claims Administrator postmarked no later than May 22, 2024.**

If you are filing a claim based on an assignment, you will have to submit documentation of your right to assert a claim with respect to those claimed purchases along with data showing the volume of purchases covered by your assignment.

In order to have a valid claim, you must be a member of the certified Direct Purchaser Class or have an assignment of rights from a Direct Purchaser Class member allowing you to recover as an assignee of a Class member. The certified Direct Purchaser Class (or “Class”) is defined as follows:

All persons or entities in the United States and its territories who purchased Lipitor or its AB-rated bioequivalent generic products directly from any of Defendants at any time during the period June 28, 2011 through May 28, 2012 (the “Class Period”).

Excluded from the Class are the Defendants and their officers, directors, management, employees, subsidiaries, or affiliates, all federal governmental entities, and all persons or entities that (i) purchased Lipitor directly from Pfizer for the first time during the Class Period after November 30, 2011, but did not purchase generic Lipitor directly from Ranbaxy during the Class Period; and (ii) all persons or entities that purchased Lipitor directly from Pfizer after November 30, 2011 that did not also purchase generic Lipitor after November 30, 2011.

Also excluded from the Class for purposes of this Settlement Agreement are the following entities: CVS Pharmacy, Inc. (which includes Caremark), Rite Aid Corporation, Rite Aid Hdqtrs. Corp., Walgreen Co. (which includes Kerr Drug), The Kroger Co. (which includes Peytons), Safeway Inc., SuperValu Inc., Meijer, Inc. and Meijer Distribution, Inc., Giant Eagle, Inc., and H-E-B L.P. (“Retailer Plaintiffs”).

The Court-approved Plan of Allocation provides, for Claimants with valid claims, that each Claimant’s allocated share of the Net Settlement Fund will be determined by taking (a) each Claimant’s weighted combined total net purchases of branded Lipitor from Pfizer from June 28, 2011 through May 29, 2014 and generic Lipitor from Ranbaxy or Watson from November 30, 2011 through May 28, 2012, (b) removing any purchases for which the rights to damages in this litigation have been assigned by agreement, and dividing it by (c) the weighted combined total purchases by all Claimants who timely submit valid, accepted Claim Forms of brand Lipitor from Pfizer from June 28, 2011 through May 29, 2014, and generic Lipitor from Ranbaxy or Watson from November 30, 2011 through May 28, 2012, net of any purchases for which the rights to damages in this litigation have been assigned by agreement. Generic Lipitor purchases will be weighted as 0.95 (95%) of a brand Lipitor purchase. This is because alleged overcharges on units of generic Lipitor were 5% less than alleged overcharges on units of brand Lipitor.

Allocations to Claimants whose right to an allocation arises by virtue of an assignment(s) from a Class member(s) would be determined in this same fashion. In these cases, the volumes of brand and generic Lipitor Tablet purchases used to determine the allocation would be the volumes assigned to the Claimant by an otherwise eligible Class member(s) (and the assignor Class member’s brand and generic Lipitor Tablet purchase volumes would be reduced by the same amount).

Please note that related documents, including the Plan of Allocation and the Court’s Order approving the Plan of Allocation, are available at <https://www.hbsslaw.com/cases/lipitor-antitrust>, <https://garwingerstein.com/settlements/in-re-lipitor-antitrust-litigation/>, and <https://bergermontague.com/cases/in-re-lipitor-antitrust-lawsuit/>. This summary of the Plan of Allocation is only a summary and is not meant to alter the terms of the Court-approved Plan of Allocation. Claimants should refer to the Plan of Allocation for further details of how the allocation will work.

INITIAL ESTIMATE OF YOUR PURCHASE VOLUMES

According to the direct purchaser plaintiffs’ economic expert’s analysis of the data produced in the Action, your net qualifying volumes of Lipitor purchases are as follows:

_____ Tablets of brand Lipitor purchased directly from Pfizer (net of returns and free samples) from June 28, 2011 through May 29, 2014.

_____ Tablets of generic Lipitor purchased directly from Ranbaxy and/or Watson (net of returns and free samples) from November 30, 2011 through May 28, 2012.

The National Drug Codes (NDCs) for the relevant products and strengths are listed below in Exhibit A.

If you accept and verify that the above figures for your net direct brand and generic Lipitor purchases are correct, please check here:

Regardless of whether you accept these figures, if you have assigned part or all of your claim by entering assignment agreements with any of the Retailer Plaintiffs (CVS Pharmacy, Inc. (which includes Caremark), Rite Aid Corporation, Rite Aid Hdqtrs. Corp., Walgreen Co. (which includes Kerr Drug), The Kroger Co. (which includes Peytons), Safeway Inc., SuperValu Inc., Meijer, Inc. and Meijer Distribution, Inc., Giant Eagle, Inc., and H-E-B L.P.), then you must submit with your Claim Form copies of those assignment agreements and data showing the volumes covered by such assignments.

Please note that, even if you accept these figures, they may be reduced if you have assigned part or all of your claim by entering an assignment agreement with any of the Retailer Plaintiffs or with any other entity. The above purchase figures do not account for assignments that may reduce these totals.

B. To the extent that you do not elect to rely upon the calculation of net purchase volumes as set forth above in Part II.A, please identify all **direct** purchases of brand Lipitor directly from Pfizer (net of returns, free samples, and assignments) from June 28, 2011 through May 29, 2014 and generic Lipitor directly from Ranbaxy or Watson (net of returns, free samples, and assignments) from November 30, 2011 through May 28, 2012, by providing the information below in electronic format. The relevant NDC codes are listed below in Exhibit A. The Claims Administrator may require additional information.

In addition, if you have assigned part or all of your claim by entering assignment agreement(s) with any of the Retailer Plaintiffs, provide data below showing the volumes covered by such assignments.

Date of Purchase (MM/DD/YYYY)	Supplier (Purchased From)	NDC (#####-####-##)	Transaction Type (Purchase or Return)	Purchase Volume # of Tablets

C. Assignments

Please check here if you are filing this claim based on an assignment:

If you are submitting a claim pursuant to an assignment, please identify with particularity that assignment here. Please also attach documentation in support of such assignment, including the assignment agreement and data showing your qualifying purchases, from your assignor, that are covered by any such assignment of brand Lipitor directly from Pfizer (net of returns, free samples) from June 28, 2011 through May 29, 2014 and generic Lipitor directly from Ranbaxy or Watson (net of returns, free samples,) from November 30, 2011 through May 28, 2012.

Please provide the following data:

Date of Purchase (MM/DD/YYYY)	Assignor (Purchased From)	NDC (#####-####-##)	Transaction Type (Purchase or Return)	Purchase Volume # of Tablets

Please note that the Claims Administrator may require additional information and documents for any claim made based on an assignment. Also please note that your claim, including the documentation and data submitted therewith, may be shared with your assignor as part of the Claims Administration process. By submitting a claim by virtue of an assignment, you are agreeing that such data and documentation, and calculations based on such data and documentation, may be shared with your assignor. Also note that, if the assignor Class member and Claimant filing by assignment from that assignor Class member cannot reach agreement about the Claimant’s right to recover, including agreement regarding the purchase volumes covered by such assignment, then the disputed share of the Net Settlement Fund shall be placed into escrow and the assignee Claimant and the assignor Class member shall make application to the Court for any such monies held in escrow.

PART III: SUBMISSION TO JURISDICTION OF THE COURT

By signing below, you agree to submit to the exclusive jurisdiction of the United States District Court for the District of New Jersey with respect to any suit, action, proceeding or dispute arising out of or relating to *In re: Lipitor Antitrust Litigation*, MDL No. 2332, No. 12-cv-2389 (D.N.J.) (the “Action”), claims administration in the Action, the claim you or any other entity is making as a Class member or assignee thereof in the Action, and/or the Releases set forth below.

PART IV: RELEASES

A. By signing below, you hereby confirm that you and your respective past and present parents, subsidiaries, and affiliates, as well your past and present general and limited partners, officers, directors, employees, agents, attorneys, servants, predecessors, successors, heirs, executors, administrators, and representatives (“Releasing Parties”) shall release and forever discharge, and covenant not to sue Pfizer and its respective past, present, and future parents, subsidiaries, divisions, affiliates, joint ventures, stockholders, general partners, limited partners, officers, directors, management, supervisory boards, insurers, employees, agents, servants, trustees, associates, attorneys and any of their legal representatives, or any other representatives thereof (and the predecessors, successors, heirs, executors, administrators, and assigns of each of the foregoing) (the “Pfizer Releasees”), with respect to, in connection with, or relating to any and all past, present, or future liabilities, claims, demands, obligations, suits, damages, penalties, levies, executions, judgments, debts, charges, actions, or causes of action,

at law or in equity, whether class, individual, or otherwise in nature, and whether known or unknown, arising out of or relating to any conduct, events, or transactions up to the date of the Settlement Agreement, (a) alleged, or which could reasonably have been alleged, in the Direct Purchaser Class Action, (b) concerning purchases of Lipitor and/or its generic equivalents and arising under the Sherman Act, 15 U.S.C. §§ 1 & 2, *et seq.*, any state or federal RICO statutes, or any other federal or state statute or common law doctrine relating to antitrust, fraud, unfair competition, unjust enrichment, or consumer protection, or (c) the sale, marketing, or distribution of Lipitor or generic Lipitor except as provided for in Paragraphs 13(c) and 14 of the Settlement Agreement (the “Released Claims”). You will be forever barred and enjoined from commencing, instituting, prosecuting, or continuing to prosecute any action or other proceeding in any forum whatsoever, including any court of law or equity, arbitration tribunal, or administrative forum, asserting the Released Claims against the Pfizer Releasees.

B. In addition, You, on behalf of yourself and all other Releasing Parties, expressly waive, release and forever discharge, upon the Settlement becoming final, any and all provisions, rights and benefits conferred by Section 1542 of the California Civil Code, which reads:

Section 1542. General Release; extent. A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party;

or by any law of any state or territory of the United States or other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to Section 1542 of the California Civil Code. The Releasing Parties may hereafter discover facts other than or different from those which he, she or it knows or believes to be true with respect to the claims which are the subject matter of Paragraph 13 of the Settlement Agreement, but You hereby expressly waive and fully, finally, and forever settle, release, and discharge, upon the Settlement Agreement becoming final, any known or unknown, suspected or unsuspected, asserted or unasserted, contingent or non-contingent claim that would otherwise fall within the definition of Released Claims, whether or not concealed or hidden, without regard to the subsequent discovery or existence of such different or additional facts. You also hereby expressly waive and fully, finally and forever settle, release and discharge any and all claims You and the Releasing Parties may have against any Pfizer Releasee under Section 17200, *et seq.*, of the California Business and Professions Code or any similar comparable or equivalent provision of the law of any other state or territory of the United States or other jurisdiction, which claims are expressly incorporated into the definition of Released Claims.

C. In addition, upon the Settlement becoming final, Pfizer on behalf of itself and its respective past, present, and future parents, subsidiaries, associates, affiliates, officers, directors, employees, insurers, general or limited partners, divisions, agents, attorneys, servants, trustees, joint ventures, heirs, executors, administrators, representatives (and the parents’, subsidiaries’, and affiliates’ past and present officers, directors, employees, agents, attorneys, servants, and representatives), and their predecessors, successors, heirs, executors, administrators, and representatives (collectively, the “Pfizer Releasers”), also release and forever discharge, and covenant not to sue, Direct Purchaser Class Members and their past, present, and future parents, subsidiaries, divisions, affiliates, joint ventures, stockholders, officers, directors, management, supervisory boards, insurers, general or limited partners, employees, agents, attorneys, servants, representatives (and the parents’, subsidiaries’, and affiliates’ past, present, and future officers, directors, employees, agents, attorneys, servants, and representatives), and the predecessors, successors, heirs, executors, administrators and representatives of each of the foregoing (collectively, the “Direct Purchaser Class Releasees”) from all claims, debts, obligations, demands, actions, suits, causes of action, damages whenever incurred, liabilities of any nature whatsoever, including costs,

expenses, penalties and attorneys' fees, under federal or state laws, whether known or unknown, foreseen or unforeseen, suspected or unsuspected, contingent or non-contingent, in law or equity, asserted in connection with the Action or that should have been asserted in the Action as compulsory counterclaims arising out of the alleged conduct that is the subject matter of Paragraph 13 of the Settlement Agreement.

D. The Settlement Agreement releases only the Pfizer Releasees and the Direct Purchaser Class Releasees with respect to the Released Claims. The Direct Purchaser Releasers specifically do not intend the Settlement Agreement, or any part hereof or any other aspect of the proposed Settlement Agreement, to compromise or otherwise affect in any way any rights the Direct Purchaser Releasers have or may have against any other person, firm, association, or corporation whatsoever. The release set forth in Paragraph 13 of the Settlement Agreement is not intended to and shall not release any claims other than the Released Claims.

E. The intent of the Settlement is to effect a complete and total resolution of this Action to the extent of the claims of the Direct Purchaser Class against Pfizer, as well as any compulsory counterclaims of Pfizer relating to the allegations in this Action that were or should have been asserted, and the Settlement is not intended to release any claims (1) arising in the ordinary course of business between any Direct Purchaser Class member and Pfizer arising under Article 2 of the Uniform Commercial Code (pertaining to sales), the laws of negligence or product liability or implied warranty, breach of contract, breach of express warranty, or personal injury; (2) unrelated to purchases of Lipitor or generic Lipitor; or (3) arising out of or in any way relating to the alleged horizontal price-fixing agreements between Pfizer and other manufacturers of generic pharmaceutical products that are alleged in *In re Generic Pharmaceuticals Pricing Antitrust Litig.*, MDL No. 2724, 16-MD-2724 (E.D. Pa.).

F. The releases set forth above will become effective when the Settlement receives final court approval.

PART V: VERIFICATION/RELEASE

I declare under penalty of perjury under the laws of the United States of America that the foregoing information provided by the undersigned is true and correct and that this proof of claim and release was executed this _____, day of _____, _____ in _____, _____
(Day) (Month) (Year) (City) (State/Country)

Sign your name here: _____

Type/print your name here: _____

Type/print your company name here: _____

Capacity or job title of person signing (e.g., President, Partner): _____

RETURN YOUR COMPLETED PROOF OF CLAIM AND RELEASE AND RETURN TO:

In re: Lipitor Antitrust Litigation

c/o RG/2 Claims Administration

P.O. Box 59479

Philadelphia, PA 19102-9479

Questions? Contact the Notice and Claims Administrator at 866-742-4955.

Remember, your signed Proof of Claim and Release must be mailed and postmarked by May 22, 2024.

Again, if you have assigned part or all of your claim by entering assignment agreements with any of the Retailer Plaintiffs (CVS Pharmacy, Inc. (which includes Caremark), Rite Aid Corporation, Rite Aid Hdqtrs. Corp., Walgreen Co. (which includes Kerr Drug), The Kroger Co. (which includes Peytons), Safeway Inc., SuperValu Inc., Meijer, Inc. and Meijer Distribution, Inc., Giant Eagle, Inc., and H-E-B L.P.), then you must submit with your Claim Form copies of those assignment agreements and data showing the volumes covered by such assignments.

Exhibit A: Relevant NDCs of Brand and Generic Lipitor

<u>NDC</u>	<u>Strength</u>	<u>Package Size</u>
<u>Brand Lipitor (Pfizer):</u>		
00071015523	10MG	90
00071015534	10MG	5000
00071015540	10MG	100
00071015623	20MG	90
00071015640	20MG	100
00071015694	20MG	5000
00071015723	40MG	90
00071015740	40MG	100
00071015773	40MG	500
00071015788	40MG	2500
00071015823	80MG	90
00071015873	80MG	500
00071015888	80MG	2500
00071015892	80MG	64
<u>Generic Lipitor (Ranbaxy):</u>		
63304082705	10MG	500
63304082790	10MG	90
63304082805	20MG	500
63304082890	20MG	90
63304082905	40MG	500
63304082990	40MG	90
63304083005	80MG	500
63304083090	80MG	90
<u>Generic Lipitor (Watson):</u>		
00591377410	10MG	1000
00591377419	10MG	90
00591377510	20MG	1000
00591377519	20MG	90
00591377605	40MG	500
00591377619	40MG	90
00591377705	80MG	500
00591377719	80MG	90